Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may […]
Author: SleepWorld Magazine
Nox Medical Redefines Sleep Diagnostics with AI, Cloud and Home Sleep Testing as a Service
Nox Medical, a global leader in sleep diagnostic solutions, is proud to unveil the expanded capabilities of Nox Connect™, a secure, cloud-based platform that now features Artificial Intelligence, web-based scoring and interpretation, and a fully integrated Home Sleep Testing Service. The new platform features will be showcased at the SLEEP […]
The Accuracy of Home Sleep Testing
Home sleep tests (HSTs) have emerged as a convenient and cost-effective alternative to traditional in-lab polysomnography (PSG) for diagnosing sleep disorders, particularly obstructive sleep apnea (OSA). Over the years, HST technology has advanced significantly, leading to improvements in accuracy and reliability. In this article, I will explore the accuracy of […]
DormoVision X Launches at SLEEP 2025
Revolutionizing sleep health with an all-in-one, AI-driven diagnostics platform. Delivering real-time physiological data monitoring and sleep analysis that matches the accuracy and quality of in-lab studies, with the comfort and convenience of at-home testing. Dormotech, a leader in advancing sleep diagnostics through innovative, clinically validated solutions, is proud to launch […]
Emerging OSA Treatments and the Evidence
Neuroscientists have found the average person processes roughly 74 gigabytes of information every day.1 That is the equivalent of watching 16 movies, reading more than 200,000 words, or scrolling on TikTok for approximately 200 hours. In other words, we are inundated with information from every angle — social media, websites, […]
Avadel Pharmaceuticals Presents New Data on LUMRYZ ER at SLEEP 2025
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 […]
Are We Truly Open to Change in the Approach to OSA?
Although there are more than half a billion individuals worldwide affected by moderate to severe obstructive sleep apnea (OSA), the vast majority still remain undiagnosed and many are untreated.1-2 Healthcare in the United States is facing shortages at every level—and these shortages are projected to increase sharply over the next […]
The Diagnostic Journey for Narcolepsy
In previous editions, we’ve talked a lot about how diagnosis is only the first part of the journey with narcolepsy. It’s true that there are many pieces to managing the disorder that follow, but that diagnosis is something we really want to hone in on in this edition. The information […]
Axsome Therapeutics Settles SUNOSI Patent Litigation with Hetero Labs Ltd.
Axsome Therapeutics, Inc. a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which […]
CO2 Monitoring in Pediatric Sleep Studies
When it comes to pediatric sleep studies, transcutaneous monitoring plays a crucial role in providing optimal care for young patients. At the Nemours Children’s Hospital Pediatric Sleep Center in Orlando, Florida, CO2 monitoring is integrated into therapist-driven protocols to ensure accurate diagnosis and optimal management of sleep-disordered breathing for pediatric […]













